PMS61 Rapid Reductions in Fatigue and Sleep Problems and Correlation with Improvements in Patient-Reported Outcomes in Patients with Active RA Treated with Certolizumab Pegol in the realistic 12-Week Phase IIIB Randomised Controlled Study

Autor: Pope, J., Fleischmann, R., Dougados, M., Bingham, C.O., Massarotti, E., Wollenhaupt, J., Duncan, B., Coteur, G., Weinblatt, M.E.
Zdroj: In Value in Health 2011 14(7):A313-A313
Databáze: ScienceDirect